Cargando…

The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential

Leukocyte cell-derived chemotaxin-2 (LECT2, also named ChM-II), initially identified as a chemokine mediating neutrophil migration, is a multifunctional secreted factor involved in diverse physiological and pathological processes. The high sequence similarity of LECT2 among different vertebrates mak...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Ming-Hui, Liu, Yan-Jun, Li, Chang-Yun, Tao, Fan, Yang, Guan-Jun, Chen, Jiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034042/
https://www.ncbi.nlm.nih.gov/pubmed/36969200
http://dx.doi.org/10.3389/fimmu.2023.1158083
_version_ 1784911122158059520
author Zhu, Ming-Hui
Liu, Yan-Jun
Li, Chang-Yun
Tao, Fan
Yang, Guan-Jun
Chen, Jiong
author_facet Zhu, Ming-Hui
Liu, Yan-Jun
Li, Chang-Yun
Tao, Fan
Yang, Guan-Jun
Chen, Jiong
author_sort Zhu, Ming-Hui
collection PubMed
description Leukocyte cell-derived chemotaxin-2 (LECT2, also named ChM-II), initially identified as a chemokine mediating neutrophil migration, is a multifunctional secreted factor involved in diverse physiological and pathological processes. The high sequence similarity of LECT2 among different vertebrates makes it possible to explore its functions by using comparative biology. LECT2 is associated with many immune processes and immune-related diseases via its binding to cell surface receptors such as CD209a, Tie1, and Met in various cell types. In addition, the misfolding LECT2 leads to the amyloidosis of several crucial tissues (kidney, liver, and lung, etc.) by inducing the formation of insoluble fibrils. However, the mechanisms of LECT2-mediated diverse immune pathogenic conditions in various tissues remain to be fully elucidated due to the functional and signaling heterogeneity. Here, we provide a comprehensive summary of the structure, the “double-edged sword” function, and the extensive signaling pathways of LECT2 in immune diseases, as well as the potential applications of LECT2 in therapeutic interventions in preclinical or clinical trials. This review provides an integrated perspective on the current understanding of how LECT2 is associated with immune diseases, with the aim of facilitating the development of drugs or probes against LECT2 for the theranostics of immune-related diseases.
format Online
Article
Text
id pubmed-10034042
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100340422023-03-24 The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential Zhu, Ming-Hui Liu, Yan-Jun Li, Chang-Yun Tao, Fan Yang, Guan-Jun Chen, Jiong Front Immunol Immunology Leukocyte cell-derived chemotaxin-2 (LECT2, also named ChM-II), initially identified as a chemokine mediating neutrophil migration, is a multifunctional secreted factor involved in diverse physiological and pathological processes. The high sequence similarity of LECT2 among different vertebrates makes it possible to explore its functions by using comparative biology. LECT2 is associated with many immune processes and immune-related diseases via its binding to cell surface receptors such as CD209a, Tie1, and Met in various cell types. In addition, the misfolding LECT2 leads to the amyloidosis of several crucial tissues (kidney, liver, and lung, etc.) by inducing the formation of insoluble fibrils. However, the mechanisms of LECT2-mediated diverse immune pathogenic conditions in various tissues remain to be fully elucidated due to the functional and signaling heterogeneity. Here, we provide a comprehensive summary of the structure, the “double-edged sword” function, and the extensive signaling pathways of LECT2 in immune diseases, as well as the potential applications of LECT2 in therapeutic interventions in preclinical or clinical trials. This review provides an integrated perspective on the current understanding of how LECT2 is associated with immune diseases, with the aim of facilitating the development of drugs or probes against LECT2 for the theranostics of immune-related diseases. Frontiers Media S.A. 2023-03-09 /pmc/articles/PMC10034042/ /pubmed/36969200 http://dx.doi.org/10.3389/fimmu.2023.1158083 Text en Copyright © 2023 Zhu, Liu, Li, Tao, Yang and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhu, Ming-Hui
Liu, Yan-Jun
Li, Chang-Yun
Tao, Fan
Yang, Guan-Jun
Chen, Jiong
The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential
title The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential
title_full The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential
title_fullStr The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential
title_full_unstemmed The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential
title_short The emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: From mechanisms to therapeutic potential
title_sort emerging roles of leukocyte cell-derived chemotaxin-2 in immune diseases: from mechanisms to therapeutic potential
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10034042/
https://www.ncbi.nlm.nih.gov/pubmed/36969200
http://dx.doi.org/10.3389/fimmu.2023.1158083
work_keys_str_mv AT zhuminghui theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT liuyanjun theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT lichangyun theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT taofan theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT yangguanjun theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT chenjiong theemergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT zhuminghui emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT liuyanjun emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT lichangyun emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT taofan emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT yangguanjun emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential
AT chenjiong emergingrolesofleukocytecellderivedchemotaxin2inimmunediseasesfrommechanismstotherapeuticpotential